Ophthalmic Consultants of Long Island Inject Patient With JETREA

Daniel Kiernan, MD, of Ophthalmic Consultants of Long Island injected a patient suffering from vitreo-macular adhesion with JETREA, a dilution of ocriplasmin that is the first FDA approved drug to treat VMA, according to a report by the Times Union.

Advertisement

This procedure was the first injection of the drug on Long Island.

JETREA, approved by the FDA in 2012, will be available at other Ophthalmic Consultants of Long Island locations.

More Articles on Ophthalmology:
Dr. Ryan Walsh Joins Medical College of Wisconsin
Miller School of Medicine, International Team Discover Seven Genes Linked to Macular Degeneration
Report Estimates Optical Imaging Market Worth $1.9B by 2018

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Ophthalmology

Advertisement

Comments are closed.